Navigation Links
Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals' siRNA Drugs In Multiple Fully Enrolled Clinical Trials
Date:11/19/2009

siRNA by advancing its clinical-stage programs, and our momentum is accelerating as we enrich the Company's pipeline and bring more product candidates into the clinic," said Daniel Zurr, Ph.D., President and Chief Executive Officer of Quark Pharmaceuticals. "Over the next 15 months, we anticipate at least one program may proceed into Phase 3 registration studies, we will report data from multiple clinical studies and we plan to file our fifth IND. We have demonstrated we have the right team and the right strategy, and we are excited about the Company's future."

Dr. Shai Erlich, Quark's Chief Medical Officer, stated, "Quark's discovery and development efforts remain focused on the goal of bringing novel and clinically relevant therapeutic options to health care providers. We do this by addressing molecular pathways that previously were not accessible to more traditional forms of pharmaceutical modulation. Quark is generating novel siRNA drug candidates and is pursuing a variety of delivery mechanisms to expand the scope of potential disease applications while eliminating the need to depend on extensive drug modifications and elaborate formulations that could reduce the therapeutic index for patients. To date, preliminary results from Quark's Phase 1 clinical studies have shown few adverse drug reactions and no treatment emergent dose-limiting toxicities. I look forward to the next stage when the company reports completed study results findings in a range of disease indications."

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc., is a leader in the discovery and development of novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. The Company's technology platform includes novel disease targets and siRNA structures and chemistry, providing Quark with freedom to operate in the siRNA intellectual property ar
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
2. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
3. Quark Pharmaceuticals Presents at Asia TIDES Conference
4. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
5. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
6. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
7. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
11. Quark Pharmaceuticals Appoints New Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 /CNW/ - On Aug. ... , the Canadian Medical Association (CMA) voted on ... any plant material, including medicinal cannabis. Bedrocan Cannabis Corp., ... supportive of the CMA motion. The CMA ... particular hazards associated with smoking any plant material, including ...
(Date:8/22/2014)... Aug. 22, 2014 Research and Markets ... Research Products: Opportunities, Tools & Technologies" report to ... stem cell research products or you wish to expand ... lucrative this market is. The authors know you want ... effectively to scientists, to generate improved revenues and take ...
(Date:8/22/2014)... Mich. , Aug. 22, 2014  Dr. ... Who with the Diamond Lifetime Achievement Award in the ... as CEO of Cardiovascular Clinical Associates. Dr. ... in managing all major aspects of the business; overseeing ... well as primary coronary intervention. In addition, he is ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2
... CARLSBAD, Calif., Oct. 18 Excaliard Pharmaceuticals, Inc. ... as Chairman of its Board of Directors. Mr. ... years of experience in successfully developing and commercializing ... field.  Excaliard Pharmaceuticals, Inc. is a biotechnology company ...
... Bend Research Inc. ( www.bendres.com ), a ... announced today it has extended its drug discovery ... Company ( www.bms.com ) (NYSE: BMY ... Under the terms of the 3-year agreement, Bristol-Myers ...
Cached Medicine Technology:Excaliard Pharmaceuticals Appoints Thomas Wiggans to Chairman of the Board 2Bend Research Announces Extension of Drug-Discovery Enablement and Development Services Agreement With Bristol-Myers Squibb 2
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- Many Americans know little ... the possibility of an outbreak in the United States, a ... they are worried that there will be a major Ebola ... they or an immediate family member will get sick with ... latest Harvard School of Public Health poll. However, those ...
(Date:8/22/2014)... York (PRWEB) August 22, 2014 ... morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in uterine surgeries continues ... Massachusetts insurance companies have decided to limit coverage ... the Worcester Telegram, Blue Cross-Blue Shield of Massachusetts ... surgeries that involve morcellation as of September 1, ...
(Date:8/22/2014)... Millennium Treatment Group, a drug ... recently launched a new website. Patients, parents, loved ... now find Millennium Treatment Group at http://www.millenniumtreatmentgroup.com ... at the beginning of July. Everything anyone would ... found on the website. There’s an About Us ...
(Date:8/22/2014)... Vegas, NV (PRWEB) August 22, 2014 ... by Kevin Richardson to restore his own vision from legally ... Shane Michaels, prompting an investigative review. , “There is ... glasses or contacts for everyday function, and most people just ... resort to corrective eye surgery that can be pretty risky ...
(Date:8/22/2014)... Beat Eczema , Susan Clark’s best-selling ... methods to completely cure the eczema symptoms they have ... Michaels, prompting an investigative review. , “Although eczema ... can still be extremely debilitating and life-altering for those ... and pain that it causes on the skin can ...
Breaking Medicine News(10 mins):Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Millennium Treatment Group Has a New Website 2Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2
... night, Oklahoma Governor Brad Henry vetoed Oklahoma House Bill ... business to conduct research that would kill a human ... risk of death or injury. The Oklahoma House ... Senate failed to follow suit.The bill would have banned ...
... Washington G-2 Reports releases top-10 trends to watch ... Demand for outpatient diagnostic imaging has never ... increase over the next three years. In fact, ... increase by double digits across all modalities (CT, ...
... can help physicians objectively assess a patient,s breast density ... changes that may suggest cancer, according to a study ... of Maryland School of Medicine, Baltimore, MD. ... estimates mammographic breast density. Results obtained by the computer ...
... (VQ) as an alternative to CT for the diagnosis ... patient exposure, according to a study performed at Albert ... NY. "VQ scanning is a nuclear test which shows ... is a pulmonary embolism, the air can enter normally, ...
... breeding techniques, shed light on human genome , , THURSDAY, April ... researchers in 25 countries has succeeded in sequencing the entire ... implications for understanding the biology of this bovine and related ... said the authors of two reports in the April 24 ...
... USA applauds President Obama,s national call for volunteerism and urges ... their local communities. President Obama recently signed a new ... learn about volunteer and service opportunities. "We need your service ... not going to tell you what your role should be. ...
Cached Medicine News:Health News:Demand for Outpatient Diagnostic Imaging Forecast to Increase by Double Digits Across All Modalities Through 2012 2Health News:New computer algorithm helps physicians determine and monitor breast density 2Health News:Scientists From 25 Countries Sequence Cow Genome 2Health News:Scientists From 25 Countries Sequence Cow Genome 3Health News:YWCA USA Applauds President Obama's National Call for Volunteer Service 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: